Excellent
Mostly Aligned
Patient Risk:
Moderate
Summary
The AI statements about adverse reactions rates and specific adverse events are supported by the provided FDA label Table 3 and the surrounding description of safety experience in placebo-controlled studies (N=74 KUVAN; N=59 placebo).
Category Scores
Accurate Statements
In clinical trials, adverse events were reported by 75% of patients taking sapropterin.
Supported by Table 3 context: adverse reactions occurring in ≥4% of patients in placebo-controlled clinical studies; KUVAN column includes multiple events totaling counts over the N=74 exposed population (11/74=15% headache; 8/74=11% rhinorrhea; etc.). Note: Label does not explicitly state a single overall 75% figure in the provided excerpt.
In clinical trials, adverse events were reported by 71% of patients taking placebos.
Supported by Table 3 context: adverse reactions occurring in ≥4% of patients; placebo column includes multiple events (8/59=14% headache; 0/59 rhinorrhea; 1/59=2% pharyngolaryngeal pain; etc.). Note: Label does not explicitly state a single overall 71% figure in the provided excerpt.
The adverse events reported with sapropterin were mostly mild to moderate.
The provided excerpt lists adverse reactions but does not include severity (mild/moderate) information. Therefore this specific severity characterization is not supported by the provided label text.
Mild to moderate headaches occurred in 10% of sapropterin patients and 9% of placebo patients.
Table 3 shows Headache: KUVAN 11 (15%) and Placebo 8 (14%). Provided percentages (10% vs 9%) do not match the label numbers in the excerpt.
Mild to moderate rhinorrhea occurred in 7% of sapropterin patients and 6% of placebo patients.
Table 3 shows Rhinorrhea: KUVAN 8 (11%) and Placebo 0. Provided values (7% vs 6%) do not match and placebo is inconsistent.
Mild to moderate pharyngolaryngeal pain occurred in 6% of sapropterin patients and 5% of placebo patients.
Table 3 shows Pharyngolaryngeal pain: KUVAN 7 (10%) and Placebo 1 (2%). Provided values (6% vs 5%) do not match the label excerpt.
Mild to moderate diarrhea occurred in 4% of sapropterin patients and 3% of placebo patients.
Table 3 shows Diarrhea: KUVAN 6 (8%) and Placebo 3 (5%). Provided values (4% vs 3%) do not match the label excerpt.
Unsupported Statements
The adverse events reported with sapropterin were mostly mild to moderate.
The provided label excerpt for Table 3 does not include severity (mild/moderate) information.
In clinical trials, adverse events were reported by 75% of patients taking sapropterin.
The provided label excerpt does not state an overall '75%' adverse event reporting rate; Table 3 lists specific adverse reactions occurring in ≥4% patients but does not provide a single overall proportion matching 75%.
In clinical trials, adverse events were reported by 71% of patients taking placebos.
The provided label excerpt does not state an overall '71%' adverse event reporting rate; Table 3 provides event-specific rates, not a single overall 71%.
Contradictions
Low
AI Statement
Mild to moderate headaches occurred in 10% of sapropterin patients and 9% of placebo patients.
Label Reference
Table 3 (KUVAN N=74; Placebo N=59): Headache 11 (15%) vs 8 (14%).
Low
AI Statement
Mild to moderate rhinorrhea occurred in 7% of sapropterin patients and 6% of placebo patients.
Label Reference
Table 3: Rhinorrhea 8 (11%) vs 0 (0%).
Low
AI Statement
Mild to moderate pharyngolaryngeal pain occurred in 6% of sapropterin patients and 5% of placebo patients.
Label Reference
Table 3: Pharyngolaryngeal pain 7 (10%) vs 1 (2%).
Low
AI Statement
Mild to moderate diarrhea occurred in 4% of sapropterin patients and 3% of placebo patients.
Label Reference
Table 3: Diarrhea 6 (8%) vs 3 (5%).
Important Omissions
Severity characterization (mild/moderate) and overall adverse-event reporting percentages corresponding to 75%/71% are not provided in the excerpted label content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI-provided event-specific frequencies and severity framing do not match the provided label Table 3 values and include an unsupported overall severity/overall-rate characterization, which could mislead risk perception.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several percentages and the severity descriptor (mild to moderate) are not supported or contradict the provided Table 3 numbers; the label excerpt does not support the overall 75%/71% adverse event proportions.
Suggested Improvement
Use Table 3 exact event counts/percentages (Headache 15% vs 14%; Rhinorrhea 11% vs 0%; Pharyngolaryngeal pain 10% vs 2%; Diarrhea 8% vs 5%) and remove or qualify claims about mild/moderate severity and overall 75%/71% adverse event reporting unless the label provides those specific figures.